News

Cushman & Wakefield has released its latest Life Sciences Lab Report on the UK's Golden Triangle. The Golden Triangle report looks closely at investment volumes, leasing take up, lab supply and pipeline, and investment into life sciences real estate across Cambridge, Oxford and London.

Q2 2024 Take-Up Statistics

• Golden Triangle leasing activity totalled 39,700 sq ft in Q2 2024.

• This lull is typical for the second quarter, with 2024 likely to be the fourth year out of the past six where Q2 has reported the lowest quarterly volume of the year.

Cambridge, UK, 23 July 2024: Metrion Biosciences Ltd (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Dr Chris Mathes, MBA, as Chief Commercial Officer (CCO). Chris will work alongside the Company’s expert leadership team to drive commercial strategy and lead global business development and marketing activities.

Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets

Metrion Biosciences appoints Dr Chris Mathes as Chief Commercial Officer


Appointment of experienced pre-clinical CRO specialist to support accelerated expansion into key global markets

Genetically engineered iPSCs offer improved efficiency and cost savings.


AMSBIO has launched a range of genetically engineered Induced Pluripotent Stem Cells (iPSCs) developed to provide improved model fidelity over cell lines and biochemical assays used for drug discovery and cell therapy research.

Astex Pharmaceuticals is pleased to share the below news which was today Issued by its collaborator The Institute of Cancer Research, London,


MHRA approves first-in-class breast cancer drug


• MHRA approves first-in-class drug Truqap (capivasertib) in combination with fulvestrant for treating HR-positive, HER-2 negative locally advanced breast cancer with specific biomarker alterations (PIK3CA, AKT1 or PTEN) alterations following recurrence or progression on or after an endocrine based regimen

Protagene has added cell based bioassay driven structure-function correlation to its extensive portfolio of MS and biophysical methods. Non GMP assays are available immediately, with GMP level assays becoming available in August.


To discuss this or any other analytical requirements, please contact colin.crowley@protagene.com


Cambridge, UK – July 17th 2024 - The Cambridge Crystallographic Data Centre (CCDC) is excited to highlight that its CSD-Particle suite of advanced informatics tools is now being actively used to revolutionize the understanding of particle behaviour and surface properties in pharmaceutical and fine chemical manufacturing. The suite provides easy to use digital methods to enhance the efficiency of product formulation and reduce manufacturing costs.

Pharmaron's DMPK Insights Podcast Episode #8: “It’s ‘All-go’ with Oligos: Challenges and Opportunities in LC-MS of Therapeutics.”

Pages